Idorsia Ltd. is a biopharmaceutical company that engages in the discovery, development, and commercialization of innovative medicines. Its primary purpose is to transform patient care through novel th... Idorsia Ltd. is a biopharmaceutical company that engages in the discovery, development, and commercialization of innovative medicines. Its primary purpose is to transform patient care through novel therapeutic solutions. Focusing on high unmet medical needs, Idorsia targets areas such as insomnia, hypertension, and rare diseases, aiming to bring breakthrough treatments to market. With a rich pipeline that spans various phases of clinical trials, the company reflects a strong commitment to research and development. Idorsia's diverse drug portfolio positions it as a significant player in the healthcare industry, particularly within the pharmaceuticals and biotechnology sectors. The company, founded in 2017 and headquartered in Allschwil, Switzerland, emerged from Johnson & Johnson’s acquisition of Actelion, emphasizing its robust scientific heritage and ambition for forward-looking innovation. In the financial markets, Idorsia Ltd. is recognized for its potential to influence therapeutic paradigms, focusing not only on the creation of new medicines but also on ensuring they reach patients in need globally. With a forward-thinking approach, Idorsia aims to contribute meaningfully to the advancement of medical science and patient health outcomes.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Financial Fundamentals data not yet covered for Idorsia

We have not yet reviewed Idorsia's disclosures for Financial Fundamentals data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Idorsia's data?

Start your 30-day free trial to request a data review for Idorsia.

Start Free Trial

Legal Center Contact Us